Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Exiqon, Rosetta Inpharmatics, BioForce Nanosciences, Affymetrix, Cogenics, NuGen Technologies, Oregon Health and Science University, GeneGo

Premium
CombiMatrix Starts Trading on Nasdaq Global Market
 
CombiMatrix’s stock began trading on the Nasdaq Global Market this week.
 
The stock had been trading on the Nasdaq Capital Market since CombiMatrix split off from its former parent company Acacia Research in August.
 
CombiMatrix, which now trades under the symbol CBMX, closed at $6.74 on Monday.
 

 
Exiqon Licenses miRNA Analysis Technology from Rosetta Inpharmatics
 
Exiqon said this week that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics. 
 
The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.
 
Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year. Financial terms of the agreement were not released.
 
“Being able to market quantitative real-time PCR products for miRNA analysis complements the current product offerings based on microarrays, in situ detection and knockdown products for miRNA research and expands Exiqon’s offerings for microRNA biomarker analysis,” said Exiqon CEO Lars Kongsbak.
 

 
BioForce Nanosciences Receives $500K from Warrant Exercise
 
BioForce Nanosciences Holdings said this week that it has received $500,000 in proceeds from an unnamed institutional investor that exercised warrants from a private financing in August.
 
The Series C warrants entitled the investor to purchase 1 million shares of BioForce’s common stock for $.50 per share. The firm’s shares closed at $.55 in Friday trade on the OTC Bulletin Board.
 
The proceeds from the exercise of the warrant are in addition to $500,000 BioForce received from the August financing.
 
“The warrant exercise proceeds provide us with the funds necessary to continue expansion of our sales and marketing efforts related to our Nano eNabler system, a device for the deposition and nanoscale manipulation of biomolecules,” said BioForce CEO Eric Henderson.
 
The firm also said the funds would support continued development of its ViriChip virus detection system.
 

 
Affymetrix Closes Offering of $275M in Senior Convertible Notes
 
Affymetrix has closed its registered offering of $275 million of senior convertible notes.
 
The company said it plans to use the funds from the sale of the unsecured, 3.5 percent notes for working capital and for general corporate purposes, which may include funding operations, acquisitions, and capital expenditures.
 
The notes will be convertible into Affymetrix common stock at a rate of 33.191 shares per $1,000 principal amount of notes, which it said is equivalent to around $30.12 a share.
 
That value represents a 39 percent premium over the firm’s closing stock price on Nov. 13, the day the offering was announced.
 

 
Cogenics to Use NuGen's Ovation Line for Affy-based Array Services
 
NuGen Technologies said last week that Cogenics will use its Ovation Systems line of RNA amplification and labeling products for use in genome services based on Affymetrix GeneChip expression arrays.
 
NuGen said the Ovation products are designed for gene expression profiling and signature discovery projects using samples from blood, fresh tissue biopsies, laser-capture microdissected cells, sorted cells, and formalin-fixed, paraffin-embedded tissue.
 
Cogenics, a subsidiary of Clinical Data, will use three of the Ovation products, including the Whole Blood Solution, the WT-Ovation Pico System and the WT-Ovation FFPE System, for target preparation with Affy arrays.
 
Financial terms of the agreement were not released.
 

 
OHSU's Microarray Core Facility Licenses GeneGo's Software Suite
 
Oregon Health and Science University has licensed several of GeneGo’s data analysis software platforms for use in its Affymetrix Microarray Core facility, GeneGo said last week.
 
Under the agreement, the OHSU microarray facility will use GeneGo’s MetaCore for pathways analysis, its MapEditor for pathway editing and communications, and its MetaLink for adding interactions to MetaCore-curated pathways.
 
The microarray facility provides RNA expression profiling and DNA variation analysis services using Affy’s GeneChip oligonucleotide arrays.
 
Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.